Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Warp Drive Bio Achieves Key Milestone in Antibiotics Collaboration with Sanofi

By Drug Discovery Trends Editor | December 5, 2016

Warp Drive Bio, Inc., a life sciences company developing therapeutics that exploit the molecules and mechanisms of nature, announced today that it has reached a pre-specified milestone in the antibiotic discovery program within the company’s research collaboration with Sanofi. From here, Sanofi will assume all preclinical and clinical research and development efforts for the novel aminoglycoside antibiotic candidates that have been discovered by Warp Drive. This program is one of several natural product-based programs that Warp Drive Bio is pursuing as a part of the company’s broader discovery efforts utilizing its novel Genome Mining technology platform.

“Antibiotic resistance is a major global public health threat, and Warp Drive is committed to deploying our unique Genome Mining Platform to discover novel medicines that address this challenge,” said Laurence E. Reid, Chief Executive Officer at Warp Drive Bio. “With the hand-off of this program to Sanofi, Warp Drive will now focus on our other programs, both anti-infectives and for other diseases, deploying our proprietary Genome Mining and SMART™ platforms. In particular, we continue to advance our RAS cancer program, which is also partnered with Sanofi.”

In January 2016, Warp Drive Bio entered into a research agreement with Sanofi that included a collaboration focused on the discovery and development of novel aminoglycoside antibiotics to treat drug-resistant Gram-negative infections. Warp Drive is eligible to receive milestones and royalties on the program. The collaboration is an outgrowth of Sanofi’s Sunrise initiative, a strategic partnership model that seeks to invest in early stage opportunities that align with Sanofi’s expert development and commercialization abilities.

 


Filed Under: Drug Discovery

 

Related Articles Read More >

Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50